EA201690863A1 - NUCLEIN-ACID REGULATION OF SPECIFIC PROTEIN GROWTH LOCK 6 (GAS6) - Google Patents

NUCLEIN-ACID REGULATION OF SPECIFIC PROTEIN GROWTH LOCK 6 (GAS6)

Info

Publication number
EA201690863A1
EA201690863A1 EA201690863A EA201690863A EA201690863A1 EA 201690863 A1 EA201690863 A1 EA 201690863A1 EA 201690863 A EA201690863 A EA 201690863A EA 201690863 A EA201690863 A EA 201690863A EA 201690863 A1 EA201690863 A1 EA 201690863A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleic acid
gas6
modulator
nuclein
methods
Prior art date
Application number
EA201690863A
Other languages
Russian (ru)
Inventor
Кристофер Рускони
Джулиана Лейзер
Сэнджой К. Маханти
Кристофер Л. Десиантис
Кейти Редик
Original Assignee
ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" filed Critical ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Publication of EA201690863A1 publication Critical patent/EA201690863A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Abstract

Настоящее изобретение, в общем, относится к фармакологической системе для модулирования биологии тромбоцитов на основе нуклеиново-кислотных лигандов, которые могут взаимодействовать с и модулировать активность специфического белка гена блокировки роста 6 (GAS6). Эти нуклеиново-кислотные лиганды активно обратимы при использовани модулятора, который ингибирует активность нуклеиново-кислотного лиганда и нейтрализует его фармакологический эффект, тем самым восстанавливая функцию GAS6. Также предлагаются композиции, содержащие нуклеиново-кислотный лиганд, лиганд и модулятор, способы получения нуклеиново-кислотного лиганда и его модулятора, способы определения характеристик нуклеиново-кислотного лиганда, а также способы применения этих агентов и композиций в медицинских терапевтических и диагностических процедурах.The present invention relates in general to a pharmacological system for modulating platelet biology based on nucleic acid ligands that can interact with and modulate the activity of a specific growth block 6 protein (GAS6) gene. These nucleic acid ligands are actively reversible by using a modulator that inhibits the activity of nucleic acid ligand and neutralizes its pharmacological effect, thereby restoring the function of GAS6. Also provided are compositions comprising a nucleic acid ligand, a ligand and a modulator, methods for producing a nucleic acid ligand and its modulator, methods for determining characteristics of the nucleic acid ligand, as well as methods for using these agents and compositions in medical therapeutic and diagnostic procedures.

EA201690863A 2012-10-24 2013-10-17 NUCLEIN-ACID REGULATION OF SPECIFIC PROTEIN GROWTH LOCK 6 (GAS6) EA201690863A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717949P 2012-10-24 2012-10-24
PCT/US2013/065521 WO2014066142A1 (en) 2012-10-24 2013-10-17 Nucleic acid regulation of growth arrest-specific protein 6 (gas6)

Publications (1)

Publication Number Publication Date
EA201690863A1 true EA201690863A1 (en) 2016-09-30

Family

ID=50545127

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690863A EA201690863A1 (en) 2012-10-24 2013-10-17 NUCLEIN-ACID REGULATION OF SPECIFIC PROTEIN GROWTH LOCK 6 (GAS6)

Country Status (2)

Country Link
EA (1) EA201690863A1 (en)
WO (1) WO2014066142A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
US11529587B2 (en) 2019-05-03 2022-12-20 Cellphire, Inc. Materials and methods for producing blood products
EP4013496A4 (en) 2019-08-16 2023-10-18 Cellphire Inc. Thrombosomes as an antiplatelet agent reversal agent
WO2021158625A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc Methods of treating acquired hemophilia with anti-fibrinolytic loaded platelets

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078778A1 (en) * 2000-04-13 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie (Vib) USE OF INHIBITION OF A Gas6 FUNCTION OR OF A Gas6 RECEPTOR FOR PREVENTING AND TREATING A CARDIOVASCULAR DISEASE
JP4773684B2 (en) * 2001-05-25 2011-09-14 デューク ユニバーシティ Drug modulator
US20110223665A1 (en) * 2008-07-25 2011-09-15 Alnylam Pharmaceuticals, Inc. ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND
ES2632345T3 (en) * 2010-01-22 2017-09-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in antimetastatic therapy

Also Published As

Publication number Publication date
WO2014066142A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
EA201391019A1 (en) CONNECTIONS AND METHODS FOR KINAZ MODULATION AND ALSO THE INDICATIONS TO THEIR APPLICATION
CY1119058T1 (en) IMIDAZOPYRROLIDINONE COMPOUNDS
PH12015501370A1 (en) Compounds and methods for kinase modulation, and indications therefor
MY181106A (en) Anti-lag3 antibodies and uses thereof
EA201400993A1 (en) ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, ACTIVE IN CERTAIN CONDITIONS AND METHODS OF THEIR APPLICATION
EA201791007A2 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
EA201391416A1 (en) NEW CONNECTIONS AS PROTEINKINASE MODULATORS
EA201591426A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
MX2018005332A (en) Materials and methods for treatment of glycogen storage disease type 1a.
EA201791393A2 (en) ANTIBODIES TO ErbB3 AND THEIR APPLICATION
EA201591131A1 (en) DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION
NZ746691A (en) Agents for treatment of claudin expressing cancer diseases
WO2014039714A3 (en) Compounds and methods for kinase modulation, and indications therefor
EA201690567A1 (en) ANTIBODIES AGAINST PD1 AND THEIR APPLICATION AS THERAPEUTIC AND DIAGNOSTIC MEANS
EA201290988A1 (en) STEREELECTIVE SYNTHESIS OF PHOSPHORUS-CONTAINING ACTIVE COMPOUNDS
EA201791577A1 (en) CONNECTING WITH EGFR AND C-MET MOLECULES WITH FIBRONECTIN TYPE III DOMAINS
UA117098C2 (en) Microrna compounds and methods for modulating mir-21 activity
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
EA201391682A1 (en) SUBSTITUTED DERIVATIVES OF INDAZOLS ACTIVE AS KINASE INHIBITORS
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EA201491784A1 (en) Antibodies Against Ligand Recorder B1 Bradykinin
EA202092627A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
EA201690863A1 (en) NUCLEIN-ACID REGULATION OF SPECIFIC PROTEIN GROWTH LOCK 6 (GAS6)
EA201590041A1 (en) SOLID FORM OF THE CHOLINE SALT OF VEMURAFENIB
EA201590507A1 (en) COMPOSITIONS AND METHODS PROVIDING SEQUENCES DETERMINING MALE FERTILITY